Loading...
XKRX005250
Market cap547mUSD
Dec 26, Last price  
17,780.00KRW
1D
0.28%
1Q
14.05%
Jan 2017
-25.29%
Name

Green Cross Holdings

Chart & Performance

D1W1MN
XKRX:005250 chart
P/E
—
P/S
0.39
EPS
—
Div Yield, %
3.75%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
5.86%
Revenues
2.06t
-1.04%
629,534,600,000533,618,697,000680,231,174,000832,291,097,000817,434,910,350855,344,622,740934,622,237,8301,043,840,314,4201,132,119,623,9101,353,893,060,7901,464,875,446,0901,547,971,214,0401,524,799,074,0001,719,325,650,4101,840,558,603,0002,079,559,971,0002,057,935,704,610
Net income
-54.14b
L
24,577,921,00021,360,397,00037,606,976,00067,522,188,00027,675,146,00061,546,845,80043,549,742,61056,760,788,98065,420,806,36047,176,642,04043,364,195,34018,466,539,830-30,476,551,59070,361,211,020127,657,537,37058,897,358,700-54,136,304,800
CFO
-39.65b
L
262,766,269,000167,466,117,000482,604,136,000355,618,664,000116,177,695,40036,796,180,23017,568,307,99054,542,863,2307,035,743,480-805,469,520144,482,443,82037,643,839,2907,650,391,89038,138,268,880103,769,151,07097,156,791,410-39,654,746,609
Dividend
Dec 27, 2023300 KRW/sh
Earnings
Feb 04, 2025

Profile

Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.
URL
http://www.greencross.com
IPO date
Aug 28, 1978
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,057,935,705
-1.04%
2,079,559,971
12.99%
1,840,558,603
7.05%
Cost of revenue
1,874,593,622
1,792,909,375
1,564,903,379
Unusual Expense (Income)
NOPBT
183,342,083
286,650,596
275,655,224
NOPBT Margin
8.91%
13.78%
14.98%
Operating Taxes
(9,469,931)
(29,267,887)
52,355,324
Tax Rate
18.99%
NOPAT
192,812,014
315,918,483
223,299,900
Net income
(54,136,305)
-191.92%
58,897,359
-53.86%
127,657,537
81.43%
Dividends
(29,933,111)
(31,499,998)
(32,237,786)
Dividend yield
4.03%
4.08%
2.62%
Proceeds from repurchase of equity
24,865,561
BB yield
-3.35%
Debt
Debt current
868,835,227
489,119,856
493,276,910
Long-term debt
303,165,937
529,710,069
462,283,998
Deferred revenue
15,884,214
22,693,024
24,589,660
Other long-term liabilities
46,922,339
32,133,139
114,965,547
Net debt
484,612,881
438,453,153
309,692,800
Cash flow
Cash from operating activities
(39,654,747)
97,156,791
103,769,151
CAPEX
(89,962,142)
(127,180,576)
(141,834,904)
Cash from investing activities
(134,347,170)
(283,962,799)
(110,206,964)
Cash from financing activities
140,559,850
51,336,156
(116,455,704)
FCF
155,314,505
392,131,880
192,312,949
Balance
Cash
196,111,169
239,977,438
398,394,221
Long term investments
491,277,113
340,399,333
247,473,887
Excess cash
584,491,497
476,398,773
553,840,178
Stockholders' equity
1,843,691,203
2,439,510,211
2,353,970,108
Invested Capital
2,480,345,066
2,498,679,645
2,368,121,480
ROIC
7.74%
12.98%
9.97%
ROCE
5.93%
9.52%
9.16%
EV
Common stock shares outstanding
45,402
45,402
45,402
Price
16,350.00
-3.82%
17,000.00
-37.38%
27,150.00
-34.58%
Market cap
742,318,302
-3.82%
771,829,427
-37.38%
1,232,656,997
-34.58%
EV
2,128,220,924
2,140,849,306
2,428,911,242
EBITDA
278,189,001
365,306,431
338,098,760
EV/EBITDA
7.65
5.86
7.18
Interest
53,104,000
36,475,000
27,525,000
Interest/NOPBT
28.96%
12.72%
9.99%